- The stock price of Exicure Inc (NASDAQ: XCUR) increased by over 30% pre-market today. These are some details you should know.
The stock price of Exicure Inc (NASDAQ: XCUR) – a development-stage biotechnology company developing therapeutics for neurology and other genetic disorders based on its proprietary Spherical Nucleic Acid (SNA) technology – increased by over 30% pre-market today. The company believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.
There are no company-specific reports or filings that appear to be driving up the price today. But discussions about the stock have been ramping up on social media platforms like Discord, Twitter, Facebook Groups, etc.
The discussions in these forums are citing a research report from last month. Last month, Chardan Capital Markets analyst Keay Nakae adjusted Exicure from a “Buy” rating to a “Neutral” rating with a price target of $0.40. Exicure closed at $0.16 in the previous trading session so the price target imputes a sizeable upside.
On January 14, 2022, the board of directors of Exicure promoted Elias Papadimas, the company’s current Chief Accounting Officer to the role of Chief Financial Officer of the company, effective January 17, 2022. And Papadimas was designated as the principal financial officer and principal accounting officer of the Company. Brian Bock, the company’s Chief Executive Officer remains the principal executive officer of the company. Plus Papadimas was also appointed as the corporate secretary of the Company.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.